Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sarcoma, Alveolar Soft Part 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Burkitt Lymphoma 1

Interventions

cediranib 3perifosine 2pembrolizumab 2pazopanib 2atezolizumab 2Sunitinib 2Specimen Handling 2Loperamide 2selinexor 1sargramostim 1romidepsin 1cabozantinib 1brostallicin 1atropine sulfate-diphenoxylate hydrochloride drug combination 1Warfarin 1Vitamin B 6 1Trabectedin 1Thyroxine 1Temozolomide 1Radiotherapy, Intensity-Modulated 1Radiation Dose Hypofractionation 1Pyridoxine 1Promethazine 1Prochlorperazine 1Polymerase Chain Reaction 1Petrolatum 1Neoadjuvant Therapy 1Mass Spectrometry 1Lorazepam 1Immunoglobulin G 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Sarcoma, Alveolar Soft Part × Prochlorperazine × Clear all
NCT01391962 2026-02-02

Sunitinib or Cediranib for Alveolar Soft Part Sarcoma

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
34 enrolled 22 charts
Sarcoma

Sarcoma, Alveolar Soft Part

Data powered by HemOnc (CC BY 4.0) Colophon âš¡